Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.88 USD | -0.78% | -21.61% | +33.83% |
Financials (USD)
Sales 2024 * | 153M | Sales 2025 * | 428M | Capitalization | 3.04B |
---|---|---|---|---|---|
Net income 2024 * | -356M | Net income 2025 * | -199M | EV / Sales 2024 * | 19.5 x |
Net cash position 2024 * | 72.44M | Net cash position 2025 * | 144M | EV / Sales 2025 * | 6.78 x |
P/E ratio 2024 * |
-8.34
x | P/E ratio 2025 * |
-16
x | Employees | 557 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.59% |
Latest transcript on Iovance Biotherapeutics, Inc.
1 day | -0.78% | ||
1 week | -21.61% | ||
Current month | -7.64% | ||
1 month | -11.97% | ||
3 months | +18.78% | ||
6 months | +169.98% | ||
Current year | +33.83% |
Managers | Title | Age | Since |
---|---|---|---|
Frederick Vogt
CEO | Chief Executive Officer | 50 | 16-09-29 |
Director of Finance/CFO | 51 | 20-12-13 | |
Brian Shew
CTO | Chief Tech/Sci/R&D Officer | - | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Merrill McPeak
BRD | Director/Board Member | 88 | 11-07-19 |
Director/Board Member | 56 | 16-06-06 | |
Michael Weiser
BRD | Director/Board Member | 61 | 18-03-14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.95% | 11 M€ | -6.03% | - | |
0.93% | 0 M€ | 0.00% | - | |
0.14% | 0 M€ | 0.00% | - | |
0.11% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-13 | 10.88 | -0.78% | 9,969,784 |
24-05-10 | 10.96 | -18.48% | 19,262,073 |
24-05-09 | 13.45 | +0.45% | 4,733,950 |
24-05-08 | 13.39 | -4.22% | 4,231,022 |
24-05-07 | 13.98 | +0.72% | 3,954,679 |
Delayed Quote Nasdaq, May 13, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.83% | 3.04B | |
-24.86% | 10.26B | |
-11.28% | 2.94B | |
-12.92% | 2.19B | |
-18.21% | 1.72B | |
+60.76% | 1.4B | |
+24.83% | 780M | |
-4.59% | 736M | |
-22.45% | 560M | |
-0.60% | 293M |
- Stock Market
- Equities
- IOVA Stock